Prof. Tyler Jacks, director of the Koch Institute, speaks with Meghna Chakrabarti of WBUR’s Radio Boston about cancer research in Boston. Jacks says the large number of researchers in the area “gives us a distinctive advantage,” as it provides researchers the opportunity to interact and collaborate with various institutions.
Boston Globe reporter Priyanka Dayal McCluskey writes that researchers from the Broad Institute and IBM are joining forces to examine why many cancer patients become resistant to drugs. The researchers hope this new effort could “help doctors prescribe more effective combinations of drugs for cancer patients.”
MIT researchers have developed a new technique to stop the spread of cancer cells through the body by delivering microRNAs to the site of the primary tumor, reports Hallie Smith for Boston Magazine. The technique “may correct gene disruptions that put a patient at risk of metastatic cancer,” Smith explains.
Boston Magazine reporter Dana Guth writes that MIT researchers are programming harmless strains of E. coli bacteria to destroy tumor cells. Guth explains that the programmed bacteria could be ingested or injected and “could offer a new way to stave off liver cancer.”
Prof. Susan Lindquist has been named a recipient of the Albany Medical Center Prize in Medicine and Biomedical Research, according to the AP. Lindquist’s research has raised hopes that “treatments could prevent protein ‘misfolding’ that drives degenerative conditions like Alzheimer's, Parkinson's and Lou Gehrig's disease.”
MIT researchers have developed a programmable vaccine that could be used to respond to disease outbreaks, reports Ben Gruber for Reuters. The vaccine harnesses “messenger RNA, a genetic material that can be programmed to fight any viral, bacterial or parasitic disease by provoking an amplified immune response.”
An image created by researchers at the Koch Institute that shows red nanoparticles carrying MicroRNAs to an aggressive breast tumor is featured in the National Cancer Institute Cancer Close Up project. Washington Post reporter Laurie McGinley explains that the photographs are intended to spark public interest and encourage young people to consider a career in microbiology.
In an article for the Financial Times, Laura Noonan highlights Prof. Andrew Lo’s work investigating how the theories of financial engineering could be used to fight cancer. “In cancer drug development, because the risks of failure are so high, the probability of success goes up quite dramatically if you create a portfolio,” says Lo.
A team of MIT researchers has been selected as the winner of the Koch Institute research-grant pitch competition for their work on developing a diagnostic platform for early-stage leukemia, reports Amanda Hoover for Boston.com. Hoover explains that the diagnostic method would “single out individual cells during blood tests, highlighting those affected by leukemia.”
Washington Post reporter Laurie McGinley writes that Prof. Tyler Jacks, director of the Koch Institute for Integrative Cancer Research, was named to a panel of experts that will advise the Obama administration on the cancer “moonshot” initiative and how to best “tackle some of the most promising but challenging areas in research today.”
MIT researchers have found evidence that there may be windows of opportunity during which drugs are more effective at treating cancer, reports Ariana Eunjung Cha for The Washington Post. "If we know the route to resistance," explains Prof. Michael Hemann, "we can ambush tumor cells."
MIT researchers have uncovered a potential link between a high-fat diet and increased risk of many types of cancer, reports Chukwuma Muanya for The Guardian. Muanya explains that the study “reveals the effect that a high-fat diet has on the biology of stem cells… and how this might make cancer more likely.”
Prof. Paula Hammond speaks with MSNBC’s Andrea Mitchell about why she feels it's imperative that researchers from different disciplines collaborate on cancer research. Hammond explained funding is needed to bring “scientists, clinicians, technologists together in places like the Koch Institute," where people "work collectively toward a cure.”
In an interview with the BBC, Prof. Heidi Williams argues that there should be more incentives for developing cancer prevention techniques and treatments for early-stage cancers. "If you look at drugs that get approved by the FDA, they all tend to be for very late stage cancer patients,” says Williams.
Prof. Phillip Sharp co-authored this piece for Huffington Post about VP Joe Biden’s national cancer research initiative. “The most important thing about collaboration is that it unquestionably saves lives.”